Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.
Jose
J
Lutzky
Juergen
J
Bauer
Boris C
BC
Bastian
D000368:Aged; D019943:Amino Acid Substitution / Q000235:genetics; D001005:Anus Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D005260:Female; D018698:Glutamic Acid / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D008239:Lysine / Q000235:genetics; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D017354:Point Mutation / Q000502:physiology; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D018698:Glutamic Acid; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D008239:Lysine